News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
Join federal technology transfer and regional business professionals on November 14-15, 2017 at The Universities at Shady Grove in Rockville, Maryland. Focus on day one of this Mid-Atlantic Regional Meeting is on "Challenges in the Adoption of Research Outcomes." Industry Partnering Day follows
Results from a large clinical trial in Liberia showed that two candidate Ebola vaccines pose no major safety concerns and can elicit immune responses that last for at least one year. One of the two vaccine candidate was co-developed by National Institute of Allergy and Infectious Diseases (NIAID)'s
The National Institutes of Health (NIH) announced $20 million in funding from the Stimulating Peripheral Activity to Relieve Conditions (SPARC) awards program. This program aims to transform our understanding of these nerve-organ interactions and ultimately advance the neuromodulation field toward